Therapeutic advances in the topical treatment of cutaneous leishmaniasis: A review

PLoS Negl Trop Dis. 2021 Mar 3;15(3):e0009099. doi: 10.1371/journal.pntd.0009099. eCollection 2021 Mar.

Abstract

Cutaneous leishmaniasis has been endemic since decades. Millions of cases are reported worldwide specially in developing and underdeveloped countries. There are 2 major types of cutaneous leishmaniasis based on the causating species found in different regions of the world. These include New and Old World cutaneous leishmaniasis, which are self-healing, but if not treated, these may cause severe scars and many other complications like mucosal involvement. The conventional gold standard treatment for both types is mainly intralesional or parenteral administration of antimonial. Lately, a great deal of research has been done on development of topical treatment based on single agent or combination therapy. This review summarizes the current state of literature regarding therapeutic outcome of topical treatment against cutaneous leishmaniasis caused by different species in different regions.

Publication types

  • Review

MeSH terms

  • Administration, Topical*
  • Antiprotozoal Agents / administration & dosage
  • Antiprotozoal Agents / therapeutic use*
  • Drug Combinations
  • Humans
  • Leishmania / drug effects
  • Leishmaniasis, Cutaneous / drug therapy*

Substances

  • Antiprotozoal Agents
  • Drug Combinations

Grants and funding

The author(s) received no specific funding for this work.